DNA synthesis and RNA synthesis machinery

The “DNA/RNA synthesis machinery via anthracycline intercalation and free radical generation” is not the name of a specific molecular target but rather refers collectively to the essential cellular components (DNA, RNA polymerase, topoisomerase II, and accessory proteins) involved in nucleic acid synthesis, which are disrupted by anthracycline drugs. Anthracyclines, such as doxorubicin and daunorubicin, exert their anti-cancer effects primarily through: 1) intercalating into DNA to impede polymerase progression; 2) inhibiting topoisomerase II, thereby triggering double-stranded DNA breaks; and 3) generating free radicals that cause oxidative damage[2][5][6][8]. These actions disrupt DNA/RNA synthesis and induce cell death, especially in rapidly dividing tumor cells. However, “DNA/RNA synthesis machinery” is not a standard, discrete target, but an umbrella term for processes and structures affected by anthracyclines rather than a single molecular entity. Thus, the label provided is overly broad and not a canonical therapeutic target. Key points: - This is not a precise molecular target, but a functional description of key cellular processes affected by anthracyclines. - Anthracycline drugs interact with multiple molecular targets, most notably DNA itself and topoisomerase II[2][7][8]. - Anthracyclines also generate free radicals, contributing to both anti-tumor efficacy and toxicity, particularly cardiotoxicity[6]. There is something wrong with this target: it is a process/mechanism, not a canonical single molecule or protein. The correct targets would be "DNA," "Topoisomerase II," or potentially "nucleic acid synthesis machinery," but the phrase as given is not suitable as a canonical name for a molecular target.

DNA intercalation; Inhibition of topoisomerase II; Free radical generation and oxidative stress; Disruption of chromatin and nucleosome structure